source
- Nurix to work with Roche on BTK degrader in pact worth up to $2.3BRoche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...Endpoints · 1mo ago↗ source
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1…Endpoints · 1mo ago↗ source
- #ADA26: Pfizer's monthly shot shows effect on obesity, diabetesThe long-acting GLP-1 shot that was the centerpiece of Pfizer’s acquisition of Metsera last year looks effective in patients with both obesity and diabetes, according to data presented Saturday. Be…